Article
A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease.
Lung cancer (Amsterdam, Netherlands) - 1 Jan 2014
Mariano Caroline, Bosdet Ian, Karsan Aly, Ionescu Diana, Murray Nevin, Laskin Janessa J, Zhai Yongliang, Melosky Barbara, Sun Sophie, Ho Cheryl
Abstract excerpt
INTRODUCTION: The IPASS trial demonstrated superior progression free survival for Asian, light/never smoking, advanced, pulmonary adenocarcinoma patients treated with first-line gefitinib compared to carboplatin/paclitaxel, of which 59% of those tested were epidermal growth factor receptor (EGFR)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.